Britain will provide all infants a vaccine for potentially fatal meningitis B. Britain decided to offer vaccine after it reached a price deal with GlaxoSmithKline PLC.

In 2014, government health advisers suggested the use of the Bexsero vaccine and months have been spent by the government discussing about the price. Owner of the drug is Novartis that lately sold most of its vaccines business to GlaxoSmithKline. Britain will become the first country to offer the vaccine to all babies.

Health Secretary Jeremy Hunt was proud that Britain is going to be the first country in the world to have a nationwide Men B vaccination program. According to experts, infants will be given the vaccine at two months, followed by two further doses.

The experts said that Meningitis is a bacterial infection of the lining surrounding the brain and spinal cord and children and teenagers are normally gets affected. This drug is now going to be included to the national childhood immunization scheme.

According to Hunt, MenB can be severely disabling or deadly particularly in infants and young children. Hunt is happy that they have reached to an agreement with GSK to supply the vaccine.

Talks regarding the price of the vaccine started between the department and the drug company in 2014. Sue Davie, chief executive of Meningitis said that to know that now babies will be protected against MenB is great and it is also another great step in the fight against meningitis.

"MenB has been at the top of this charity's agenda for decades and we are delighted that vaccinating all babies against this devastating disease is now within sight, cementing the UK's position as a world leader in meningitis prevention", said Chris Head, chief executive of Meningitis Research Foundation.